BTIG analyst David Larsen initiated coverage of DocGo with a Buy rating and $15 price target. During the pandemic, municipalities used DocGo to provide COVID testing and vaccinations for the homeless population, the analyst tells investors in a research note. The firm says the company has a “deep, and very robust,” technology platform that shows which care-units are available for services, where they are located, and the skills available within certain teams. The firm says DocGo continues to win larger contracts and can work across the entire healthcare and human services ecosystem to deliver value.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DCGO:
- DocGo launches partnership with EmblemHealth
- DocGo price target raised to $16 from $15 at Northland
- DocGo raises FY23 revenue view to $540M-$550M from $500M-$510M, consensus $504M
- DocGo reports Q2 EPS (2c), consensus 3c
- DCGO Upcoming Earnings Report: What to Expect?
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue